171 related articles for article (PubMed ID: 37860863)
1. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
[TBL] [Abstract][Full Text] [Related]
2. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
3. Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
[TBL] [Abstract][Full Text] [Related]
4. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
Pirillo A; Catapano AL
Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
[TBL] [Abstract][Full Text] [Related]
5. Marked plaque regression in homozygous familial hypercholesterolemia.
Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
[TBL] [Abstract][Full Text] [Related]
6. Evinacumab: Mechanism of action, clinical, and translational science.
Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
[TBL] [Abstract][Full Text] [Related]
7. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
[TBL] [Abstract][Full Text] [Related]
8. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Doggrell SA
Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
[No Abstract] [Full Text] [Related]
9. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
Khoury E; Croteau L; Lauzière A; Gaudet D
Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
[TBL] [Abstract][Full Text] [Related]
11. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
White RT; Sankey KH; Nawarskas JJ
Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
[TBL] [Abstract][Full Text] [Related]
12. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
[TBL] [Abstract][Full Text] [Related]
14. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
15. Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.
Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; McGinniss J; Gaudet D; Pordy R
JAMA Cardiol; 2023 Nov; 8(11):1070-1076. PubMed ID: 37703006
[TBL] [Abstract][Full Text] [Related]
16. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
[TBL] [Abstract][Full Text] [Related]
17. Evinacumab for treatment of familial hypercholesterolemia.
Warden BA; Duell PB
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):739-751. PubMed ID: 34253139
[No Abstract] [Full Text] [Related]
18. Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab.
Shamsudeen I; McCrindle BW; Hegele RA
JCEM Case Rep; 2023 May; 1(3):luad058. PubMed ID: 37305647
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study.
D'Erasmo L; Steward K; Cefalù AB; Di Costanzo A; Boersma E; Bini S; Arca M; van Lennep JR;
Eur J Prev Cardiol; 2022 May; 29(5):832-841. PubMed ID: 34971394
[TBL] [Abstract][Full Text] [Related]
20. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]